ArticleAfrican journal of laboratory medicine2018
Drug resistant tuberculosis in Africa: Current status, gaps and opportunities.
Article in African journal of laboratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Bagmati Province, Nepal: a matched case-control study.BMC infectious diseases · 2026Article
- Body mass index (BMI) at RR-TB diagnosis as an independent predictor of treatment outcomes: a retrospective analysis.BMC infectious diseases · 2026Article
- Risk factors and treatment outcomes of drug-resistant tuberculosis among patients attending Ndola Teaching Hospital, Zambia: a retrospective case-control study.The Pan African medical journal · 2026Article
- Factors associated with survival of tuberculosis patients in Southeast Iran: comparison of stepwise cox regression, survival tree, and random survival forest.BMC public health · 2025Article
- In vitro phytochemical, antioxidant activity and antimycobacterial potentials of selected medicinal plants commonly used for respiratory infections and related symptoms in the Limpopo Province, South Africa.BMC complementary medicine and therapies · 2025Article
- Frailty modelling for multidrug-resistant tuberculosis mortality in Namibia.Journal of public health research · 2025Article
- Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia.Journal of clinical microbiology · 2025Article
- Drug resistance profile ofFrontiers in microbiology · 2025Article
- Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.Frontiers in public health · 2025Article
- Treatment outcomes among patients with drug-resistant tuberculosis managed with BPaL/BPaLM regimen in the Southeast Zone of Nigeria.The Pan African medical journal · 2025Article
- Factors associated with tuberculosis drug resistance among presumptive multidrug resistance tuberculosis patients identified in a DRTB surveillance study in western Kenya.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Predicting Treatment Outcomes in Patients with Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection, Using Supervised Machine Learning Algorithm.Pathogens (Basel, Switzerland) · 2024Article
- Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa.Vaccines · 2024Review
- Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region.Drug safety · 2024Article
- Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021.BMC public health · 2024Article
- Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control.Frontiers in public health · 2024Review
- Policy analysis: Key milestones in MDR-TB management over the past decade in South Africa.Journal of public health in Africa · 2024Review
- Article
- Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?Clinical and translational science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization End TB Strategy targets for 2035 are ambitious and drug resistant tuberculosis is an important barrier, particularly in Africa, home to over a billion people.
objectiveWe sought to review the current status of drug resistant tuberculosis in Africa and highlight key areas requiring improvement.
methodsAvailable data from 2016 World Health Organization global tuberculosis database were extracted and analysed using descriptive statistics.
resultsThe true burden of drug resistant tuberculosis on the continent is poorly described with only 51% of countries having a formal survey completed. In the absence of this data, modelled estimates were used and reported 92 629 drug resistant tuberculosis cases with 42% of these occurring in just two countries: Nigeria and South Africa. Of the cases estimated, the majority of patients (70%) were not notified, representing 'missed cases'. Mortality among patients with multi-drug resistant tuberculosis was 21%, and was 43% among those with extensively drug resistant tuberculosis. Policies on the adoption of new diagnostic tools was poor and implementation was lacking. A rifampicin result was available for less than 10% of tuberculosis cases in 23 of 47 countries. Second-line drug resistance testing was available in only 60% of countries. The introduction of the short multi-drug resistant tuberculosis regimen was a welcome development, with 40% of countries having implemented it in 2016. Bedaquiline has also been introduced in several countries.
conclusionDrug resistant tuberculosis is largely missed in Africa and this threatens prospects to achieve the 2035 targets. Urgent efforts are required to confirm the true burden of drug resistant tuberculosis in Africa. Adoption of new tools and drugs is essential if the 2035 targets are to be met.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.